Objective To analyze the impact of secondary cytoreductive surgery (SCS) on survival outcome in a retrospective series of isolated platinum-resistant recurrent ovarian cancer. Methods We evaluate a consecutive series of 268 ovarian cancer patients with platinum-resistant relapse. Isolated recurrence was defined as the presence of a single nodule, in a single anatomic site, and was observed in 27 cases (10.1%). In all women the presence of isolated relapse was assessed at radiological evaluation, and surgically confirmed in the SCS group. Results Among the 27 patients with isolated recurrence, 16 (59.3%) received chemotherapy alone, and 11 (40.7%) complete SCS followed by non-platinum based chemotherapy. No significant differences were observed in the distribution of baseline clinico-pathological characteristics, pattern of recurrent disease, duration of PFI, and type of salvage chemotherapy between the two groups. In the SCS group, 6 patients (54.5%) showed isolated peritoneal relapse and 5 women (45.4%) showed isolated lymph nodal recurrence, and were treated with peritonectomy and lymphadenectomy, according with site of relapse. Two post-operative complications (18.2%) occurred: asymptomatic lymphocele and groin wound dehiscence. SCS significantly prolonged median time to first progression (12 months vs 3 months; p-value = 0.016), median time to second progression (8 months vs 3 months; p-value = 0.037), and post-relapse survival (PRS) (32 months vs 8 months; p-value = 0.002). Residual tumor at 1st surgery (X2 = 5.690; p-value = 0.017), duration of PFI (X2 = 5.401; p-value = 0.020), and complete SCS (X2 = 4.250; p-value = 0.039) retains independent prognostic role for PRS in multivariate analysis. Conclusions SCS prolongs PRS compared to chemotherapy alone in isolated platinum-resistant recurrent ovarian cancer. © 2014 Elsevier Inc.

Secondary cytoreductive surgery in patients with isolated platinum-resistant recurrent ovarian cancer: A retrospective analysis / Petrillo, M.; Pedone Anchora, L.; Tortorella, L.; Fanfani, F.; Gallotta, V.; Pacciani, M.; Scambia, G.; Fagotti, A.. - In: GYNECOLOGIC ONCOLOGY. - ISSN 0090-8258. - 134:2(2014), pp. 257-261. [10.1016/j.ygyno.2014.05.029]

Secondary cytoreductive surgery in patients with isolated platinum-resistant recurrent ovarian cancer: A retrospective analysis

Petrillo M.;
2014-01-01

Abstract

Objective To analyze the impact of secondary cytoreductive surgery (SCS) on survival outcome in a retrospective series of isolated platinum-resistant recurrent ovarian cancer. Methods We evaluate a consecutive series of 268 ovarian cancer patients with platinum-resistant relapse. Isolated recurrence was defined as the presence of a single nodule, in a single anatomic site, and was observed in 27 cases (10.1%). In all women the presence of isolated relapse was assessed at radiological evaluation, and surgically confirmed in the SCS group. Results Among the 27 patients with isolated recurrence, 16 (59.3%) received chemotherapy alone, and 11 (40.7%) complete SCS followed by non-platinum based chemotherapy. No significant differences were observed in the distribution of baseline clinico-pathological characteristics, pattern of recurrent disease, duration of PFI, and type of salvage chemotherapy between the two groups. In the SCS group, 6 patients (54.5%) showed isolated peritoneal relapse and 5 women (45.4%) showed isolated lymph nodal recurrence, and were treated with peritonectomy and lymphadenectomy, according with site of relapse. Two post-operative complications (18.2%) occurred: asymptomatic lymphocele and groin wound dehiscence. SCS significantly prolonged median time to first progression (12 months vs 3 months; p-value = 0.016), median time to second progression (8 months vs 3 months; p-value = 0.037), and post-relapse survival (PRS) (32 months vs 8 months; p-value = 0.002). Residual tumor at 1st surgery (X2 = 5.690; p-value = 0.017), duration of PFI (X2 = 5.401; p-value = 0.020), and complete SCS (X2 = 4.250; p-value = 0.039) retains independent prognostic role for PRS in multivariate analysis. Conclusions SCS prolongs PRS compared to chemotherapy alone in isolated platinum-resistant recurrent ovarian cancer. © 2014 Elsevier Inc.
2014
Secondary cytoreductive surgery in patients with isolated platinum-resistant recurrent ovarian cancer: A retrospective analysis / Petrillo, M.; Pedone Anchora, L.; Tortorella, L.; Fanfani, F.; Gallotta, V.; Pacciani, M.; Scambia, G.; Fagotti, A.. - In: GYNECOLOGIC ONCOLOGY. - ISSN 0090-8258. - 134:2(2014), pp. 257-261. [10.1016/j.ygyno.2014.05.029]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11388/245874
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 38
  • ???jsp.display-item.citation.isi??? 34
social impact